Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; email:
Department of Comparative Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Annu Rev Med. 2018 Jan 29;69:409-419. doi: 10.1146/annurev-med-061016-041032. Epub 2017 Oct 13.
Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in both preventive and therapeutic modalities. Multiple bNAbs have been isolated, characterized, and assessed in vitro and in vivo, but no single antibody appears to possess the breadth and potency that may be needed if it is to be used in the treatment of HIV-1 infection. With the technological advances of the past decades, novel and more effective bNAbs have been identified or engineered for higher neutralizing potency, greater breadth, and increased serum half-life. In this review, we discuss the development of a new generation of anti-HIV-1 bNAbs and their potential to be used clinically for treatment and prevention of HIV-1 infection.
广谱中和抗体（bNAbs）已被评估为对抗传染病的有前途的药物。特别是 HIV-1 特异性 bNAbs，已在预防和治疗模式中进行了测试。已经分离、鉴定和评估了多种 bNAbs，无论是在体外还是在体内，但似乎没有一种抗体具有广泛的中和效力，如果要用于治疗 HIV-1 感染，可能需要这种中和效力。过去几十年的技术进步，为提高中和效力、扩大中和范围和延长血清半衰期，已经鉴定或设计了新型更有效的 bNAbs。在这篇综述中，我们讨论了新一代抗 HIV-1 bNAbs 的发展及其在临床上用于治疗和预防 HIV-1 感染的潜力。
